The donation is dedicated to translational cancer research, meaning applied cancer research in antibody and cell therapies with the aim of improving prognosis and quality of life for today's cancer patients.
The administrative recipient is CREATE Health Translational Cancer Centre, with Carl Borrebaeck, Professor of Immunotechnology, and Kristian Pietras, Professor of Molecular Medicine, as principal investigators. The funding will be allocated over a five-year period and will go to both existing senior researchers and new recruitment.
The research will be carried out in collaboration with the Swiss Cancer Center and EPFL in Lausanne.
Read the entire article at lunduniversity.lu.se: SEK 420 million to cancer research at Lund University